Multikinase inhibitors use in differentiated thyroid carcinoma
Sina Jasim,1,* Levent Ozsari,2,* Mouhammed Amir Habra2 1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA; 2Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA *These authors con...
Enregistré dans:
Auteurs principaux: | Jasim S, Ozsari L, Habra MA |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a7502555b4a34c08a0e8a768baff9287 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Emerging role of multikinase inhibitors for refractory thyroid cancer
par: Perez CA, et autres
Publié: (2012) -
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
par: Stjepanovic N, et autres
Publié: (2014) -
DNAJB11 predicts a poor prognosis and is associated with immune infiltration in thyroid carcinoma: a bioinformatics analysis
par: Rongxin Sun, et autres
Publié: (2021) -
Anaplastic thyroid carcinoma - current issues of today (according to NCCN Guidelines)
par: O.O. Halay, et autres
Publié: (2019) -
Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
par: Iason Psilopatis, et autres
Publié: (2021)